Imperial Ginseng Products Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Imperial Ginseng Products heeft een totaal eigen vermogen van CA$265.1K en een totale schuld van CA$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk CA$299.7K en CA$34.6K.

Belangrijke informatie

Verhouding schuld/eigen vermogen

CA$0

Schuld

Rente dekkingsratio	n/a
Contant	CA$274.42k
Aandelen	CA$265.08k
Totaal verplichtingen	CA$34.57k
Totaal activa	CA$299.65k

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CA$299.7K ) IGP } overtreffen de korte termijn passiva ( CA$34.6K ).

Langlopende schulden: IGP heeft geen langlopende schulden.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: IGP is schuldenvrij.

Schuld verminderen: IGP heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 10.7% was.

Schuldendekking: IGP heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: IGP heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Imperial Ginseng Products Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

First half 2024 earnings released: CA$0.005 loss per share (vs CA$0 in 1H 2023)

Upcoming dividend of CA$2.25 per share

Imperial Ginseng Products Ltd. Announces Cash Distribution, Payable on January 26, 2024

Investor sentiment improves as stock rises 27%

New major risk - Market cap size

Insufficient new directors

First quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.11 loss in 1Q 2023)

New major risk - Market cap size

Insufficient new directors

Here's Why We Think Imperial Ginseng Products (CVE:IGP) Is Well Worth Watching

Full year 2023 earnings released: EPS: CA$0.38 (vs CA$0.31 in FY 2022)

Imperial Ginseng Products Ltd., Annual General Meeting, Dec 07, 2023

Insufficient new directors

Third quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.05 loss in 3Q 2022)

Insufficient new directors

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CA$0.11 (vs CA$0.07 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.11 loss per share (vs CA$0.22 profit in 1Q 2022)

Insufficient new directors

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: CA$0.31 (vs CA$0.61 loss in FY 2021)

Imperial Ginseng Products Ltd., Annual General Meeting, Dec 07, 2022

Less than half of directors are independent

Chairman exercised options to buy CA$50k worth of stock.

Less than half of directors are independent

Third quarter 2022 earnings released: CA$0.05 loss per share (vs CA$0.03 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Investor sentiment improved over the past week

We Think Imperial Ginseng Products' (CVE:IGP) Robust Earnings Are Conservative

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: CA$0.61 loss per share (vs CA$1.00 loss in FY 2020)

Less than half of directors are independent

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CA$0.13 (vs CA$0.07 loss in 2Q 2020)

New 90-day high: CA$0.55

How Much is Imperial Ginseng Products' (CVE:IGP) CEO Getting Paid?

New 90-day high: CA$0.37

First quarter 2021 earnings released: CA$0.57 loss per share

Full year earnings released - CA$1.00 loss per share

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven